Predictive Oncology Inc. Announces Newest Board Member
September 15 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery, is
excited to announce that Raymond F. Vennare was elected to the
Board of Directors, pursuant to action of the Board effective
September 13, 2021.
Mr. Vennare brings more than thirty years of experience as an
accomplished senior executive, board director and biotechnology
entrepreneur to Predictive Oncology, Inc. As a seasoned
professional who has founded, built and managed multiple companies
on behalf of institutional investors, private foundations and
research institutions, he is a well-respected expert in the
practice of company creation, technology commercialization,
business development and corporate governance. In 2015, Mr. Vennare
was appointed Chief Executive Officer and Chairman of the Board of
Cvergenx, Inc., a genomic informatics company developing
decision-support tools for radiation oncology. Previously, Mr.
Vennare was Co-founder, President and CEO of ThermalTherapeutic
Systems, Inc. (Medical Device); President and Chief Executive
Officer of ImmunoSite, Inc. (Diagnostics); Senior Vice President
and Chief Information Officer of TissueInformatics, Inc.
(Bioinformatics); and Founder and President of VSInteractive
(Information Technology). From June 2018 to December 2020, he
served as Vice Chairman of Guangzhou INDA Biotechnology Company,
Ltd. In 2019, he joined the Board of Directors of Cvergenx
Technologies India Private, Ltd. In addition to his board service
and company affiliations, Mr. Vennare is a frequent advisor to
organizations as diverse as nationally-ranked universities and
philanthropic foundations, to multi-national publicly traded
companies and early-stage start-ups.
"We are very excited to have Raymond join our Board of
Directors. As an accomplished executive in the field of
biotechnology, especially oncology, he will bring valuable
perspective, leadership and insight to our company,"
said Chief Executive Officer J. Melville Engle.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Skyline, Helomics and Soluble Biotech), which contain
four subsidiaries: Helomics, TumorGenesis, Skyline Medical and
Soluble Biotech.
Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. TumorGenesis Inc.
specializes in media that help cancer cells grow and retain their
DNA/RNA and proteomic signatures, providing researchers with a tool
to expand and study cancer cell types found in tumors of the blood
and organ systems of all mammals, including humans. Skyline Medical
markets its patented and FDA cleared STREAMWAY System which
automates the collection, measurement, and disposal of waste fluid,
including blood, irrigation fluid and others within a medical
facility, through both domestic and international divisions.
Soluble Biotech is a provider of soluble and stable formulations
for proteins including vaccines, antibodies, large and small
proteins and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024